Study of INBRX-109 in Conventional Chondrosarcoma


About this study

The purpose of this study is to evaluate INBRX-109 in unresectable or metastatic conventional chondrosarcoma patients.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

1. Conventional chondrosarcoma, unresectable (=inoperable) or metastatic.

2. Measurable disease by RECISTv1.1. Note: Tumor lesions located in a previously
irradiated (or other locally treated) area will be considered measurable, provided
there has been clear imaging-based progression of the lesions since the time of

3. Radiologic progression of disease per RECISTv1.1 criteria within 6 months prior to
screening for this study.

4. Adequate hematologic, coagulation, hepatic and renal function as defined per protocol.

5. Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1.

6. Estimated life expectancy of at least 12 weeks.

7. Availability of archival tissue or fresh cancer biopsy are mandatory.

Exclusion Criteria:

1. Any prior exposure to DR5 agonists.

2. Allergy or sensitivity to INBRX-109 or known allergies to CHO-produced antibodies.

3. Non-conventional chondrosarcoma, e.g., clear-cell, mesenchymal, extraskeletal myxoid,
myxoid, and dedifferentiated chondrosarcoma.

4. Prior or concurrent malignancies. Exception: Patients with a prior or concurrent
malignancy whose natural history or treatment does not have the potential to interfere
with the safety or efficacy assessments.

5. Chronic liver diseases. Exception: Patients with fatty liver disease are acceptable as
long as adequate hepatic function as defined in the inclusion/exclusion criteria is

6. Evidence or history of multiple sclerosis (MS) or other demyelinating disorders.

7. Other exclusion criteria per protocol.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Eligibility last updated 5/31/23. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

Steven Attia, D.O.

Open for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office


Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Mahesh Seetharam, M.D.

Open for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information


Publications are currently not available

Additional contact information

Cancer-related trials contact form

Phone: 855-776-0015 (toll-free)

International patient clinical studies questions